Hydrix secures A$3.4 million medical Robotics development contract with US-based Remedy Robotics. Posted: 20th July 2026 ASX Announcement * Hydrix to support development of safety-critical software and embedded electronics for Remedy's next generation N1 robotic platform for endovascular intervention * The Contract reinforces Hydrix's position as a specialist engineering partner in advanced medical robotics, one of the fastest-growing segments of the global medical technology industry * According to Grand View Research, The US advanced medical Robotics market was valued at $3.84 billion in 2025, with projected 13.1% CAGR from 2026 to 2033 * Based on the agreed scope of work, to be undertaken on a time-and-materials basis, Hydrix expects the contract to generate approximately A$3.4 million in revenue. * Revenue will be recognised progressively in FY2027 and is >50% of Hydrix's current market capitalisation Hydrix Limited (ASX: HYD) (Hydrix) is pleased to announce it has secured a significant (A$3.4M) engineering development contract with US-based physical AI company Remedy Robotics. The agreement significantly expands Hydrix's existing multi-year relationship with Remedy Robotics and continues Hydrix's international expansion strategy focused on delivering mission-critical medical technologies, including advanced robotics, AI-enabled systems and Class II and III medical devices. Remedy Robotics is developing an AI-enabled robotic platform, the N1 System, for cardiovascular intervention, designed to enable experienced clinicians to perform complex endovascular procedures with increased precision and remotely over vast distances. Working with leading clinicians from around the world, including in Australia through its clinical partnership with the Australian Stroke Alliance, Remedy aims to radically expand access to specialist stroke and cardiovascular intervention regardless of patient location. Dr David Bell, Co-Founder and Chief Executive Officer, Remedy Robotics

Remedy Robotics has secured $35M to advance remote stroke treatment solutions. This funding aims to transform stroke care by overcoming geographical and logistical barriers, making it more accessible and efficient. Strokes are a major global health issue, being the second leading cause of death and third leading cause of disability. Traditional stroke treatment requires immediate intervention, which is often delayed, increasing the risk of long-term disability or death.